Shuttle Pharmaceuticals Holdings, Inc. Logo

Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):
US8256933024
LEI:
Country:
United States of America
Address:
401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea
260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea
014570
Korro Bio, Inc. Logo
A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.
United States of America
KRRO
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan
4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan
4884
Krka Logo
Develops and sells generic prescription, non-prescription, and animal health products globally.
Slovenia
KRKG
Krystal Biotech, Inc. Logo
Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.
United States of America
KRYS
KUKJEON PHARMACEUTICAL Co.,Ltd Logo
A chemical solutions provider manufacturing Active Pharmaceutical Ingredients and electronic materials.
South Korea
307750
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
KWANGDONG PHARMACEUTICAL CO.,LTD Logo
Developing drugs & health goods by integrating oriental and Western medicine.
South Korea
009290

Talk to a Data Expert

Have a question? We'll get back to you promptly.